Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive Officer
April 29 2024 - 2:00AM
Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome
therapeutics company, announces that Dr. Per Lundin, Co-Founder and
Chief Business Officer, has been appointed as Chief Executive
Officer (CEO) of the Company and will be appointed to its Board of
Directors. Following more than six years with the Company, Dr.
Antonin “Tony” de Fougerolles has decided to step down as CEO and
Director of Evox. Tony will continue to support the Company as a
strategic adviser.
Per has more than 15 years’ experience founding,
leading, and advising biotech companies developing advanced
therapies, including co-founding Evox in 2016. Prior to Evox, he
founded and led IsletOne Therapeutics, a cell therapy company
developing allogeneic cell therapies for autoimmune and
inflammatory diseases, and prior to that worked in business
development and as an IP attorney in a leading European law firm.
Per serves as non-executive director of publicly listed gene
therapy company Combigene and research committee member and board
director of JDRF International and JDRF UK, respectively. He is a
qualified European Patent Attorney with extensive leadership,
business development and operational experience; he earned his PhD
from the Karolinska Institute, his Master of Science in
Biotechnology Engineering from the Royal Institute of Technology,
and his Master of Business Administration from Stockholm University
School of Business.
Per takes on the role of CEO having founded the
Company in 2016 and worked closely with Tony over the last six and
a half years to significantly progress the business. Evox is backed
by leading venture capital investors and has since inception
developed a proprietary exosome therapeutics platform technology,
entered into a number of collaborations with renowned institutions
and pharma companies, developed a dominant IP estate and advanced
the Company’s proprietary pipeline towards the clinic.
“On behalf of the Board and the whole Evox team,
I would like to thank Tony for his leadership and commitment to
driving the Company and its innovative technology forward, and wish
him all the best in the next phase of his career,” said Paul
Carter, Non-Executive Chairman of Evox Therapeutics. “Per’s
strategic insight and wide-ranging experience will be invaluable as
he leads Evox through its next phase of growth. Furthermore, as
Co-Founder of the business, he has a deep understanding of Evox and
its exosome platform.”
“Over the past six and a half years as CEO, I am
extremely proud of the progress we have made to uncover the
enormous potential of exosome therapeutics,” said Dr. Antonin de
Fougerolles, outgoing CEO. “The Company has a very promising future
ahead and I look forward to continuing to support Evox’s journey in
an advisory role.”
Per Lundin, PhD, Chief Executive Officer and
Co-Founder of Evox Therapeutics, added: “I have enjoyed working
closely with Tony over the years and I look forward to leading the
Company as we advance our cutting-edge technology, DeliverEX®, to
accelerate the development of exosome-enabled genetic
medicines.”
About Evox Therapeutics
Evox Therapeutics is a privately held,
Oxford-based biotechnology company that is a leader in harnessing
and engineering the natural delivery capabilities of exosomes to
create and enable the next generation of genetic medicines. Evox
uses its DeliverEX® platform to engineer exosomes to facilitate
safe and precise drug delivery to hard-to-reach organs and tissues.
The Company holds an unrivalled intellectual property estate across
non-viral genetic medicines and is backed by leading life sciences
venture capital groups, including Oxford Science Enterprises,
Redmile, OrbiMed and GV.
For media enquiries, please contact:
Media:Simon Conway / Natalie
Garland-CollinsEvoxTherapeutics@fticonsulting.com +44 (0) 203 727
1000
For further information visit: www.evoxtherapeutics.com